We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Insights On Right To Try Act And 'Expanded Access' Concerns

Law360 (December 18, 2018, 11:12 AM EST) -- In an earlier article authored by Ropes & Gray LLP attorneys, we summarized the implications of the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the RTT.[1] President Donald Trump signed the RTT into law in May 2018 to provide patients who are not eligible for enrollment in a clinical trial with a pathway to obtain investigational drugs or biologics for therapeutic use. There is an existing expanded access, or EA, pathway, however, referred to colloquially as “compassionate use,” that also provides access to investigational products for therapeutic use. Generally, under both pathways,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS